Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. - Wikidata - wikimedia - TriplyDB

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

http://www.wikidata.org/entity/Q45250378

about

Current Trends of Renal Impairment in Multiple Myeloma International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy Management of multiple myeloma with bortezomib: experts review the data and debate the issues.Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma Bortezomib in patients with renal impairment.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Bortezomib: the evidence of its clinical impact in multiple myeloma.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Proteasome inhibitors in the treatment of multiple myeloma Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma Determination of intrarenal resistance index (RI) in patients with multiple myeloma.Proteasome inhibition as a therapeutic strategy for hematologic malignancies.Pulmonary toxicity from novel antineoplastic agents.Pharmacotherapy of multiple myeloma.Bortezomib for multiple myeloma.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.Lenalidomide in multiple myeloma.VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.The pathogenesis of the bone disease of multiple myeloma.Current therapy of myeloma induced renal failure.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Treatment of relapsed and refractory myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspective Kidney disease associated with plasma cell dyscrasias Guidelines for supportive care in multiple myeloma 2011.Guidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.Current strategies for treatment of relapsed/refractory multiple myeloma.

P2860

Q26740444-6B67B636-2C62-458B-BF3C-41B27DDE4A52 Q27002668-94DBC725-6CC0-4348-A011-EABA714F1FA2 Q27003218-AB14C28A-BA3E-4CB0-920E-BC9DA07D7570 Q31098282-5BD4BB95-7A33-4203-83C9-E10DBB1BE326 Q33379044-0DB3AB3E-714D-4574-AC0F-99CB3DF0FD4B Q33396250-DC97F091-BD05-4B4F-9B93-0E6BADBDF6E9 Q33398587-D3B0C30B-2BAC-41D9-AB90-C8347D631807 Q33400724-6D25F41E-8E93-4F01-AC1D-D24273FA690E Q33407105-42BE3550-1952-41F8-B82E-D33E4521AFE7 Q33408056-E9EA2E95-024C-41BB-84A9-D3CE831F22AB Q33558161-8C9B2811-C99C-481F-8EFE-B00407B8A32D Q34611676-C0C84091-2B3F-4478-8E43-A1B7E3ECC79E Q34666924-A120E41C-99E8-43FA-8661-E75BFCC2E1C2 Q35063100-B8B107FC-61F2-4210-BD85-58281B771D35 Q35959247-6D164656-AA43-4B27-94D2-218241D0666D Q36185620-7EE131D7-43E6-48CF-BA22-E0972CAEFE57 Q36314452-75C7B5E4-A4EB-4295-AF13-45282BEBF88C Q36429735-0AEE1A77-8E59-432B-9204-5B3EF27C44F5 Q36521862-49BD452C-739A-4420-B6B2-9F0E005A8021 Q36523911-C7C9DC78-D9F9-4A98-8D22-0CAF9395407B Q36544596-51719974-FB8B-45E0-A910-04DF446A5245 Q36573818-7D62F759-436B-4F71-BE71-8037F57241D8 Q36878944-0DC9810E-81CE-47FA-A242-C98B75CC2EEA Q37112901-603F3318-CC01-455F-9A8F-7D09E4B44F0D Q37136324-D2C47708-C520-4B63-B1A1-F627871A9172 Q37152741-312EC9E0-B3B8-48A7-9BD3-C39A04E6B051 Q37157442-AF771785-A23B-4071-9AFF-D40699C1376B Q37209929-FAE814C0-45AE-43D0-B1EE-F248CF9E3914 Q37677935-6A0CCA96-923C-438E-A118-C303242E3548 Q37750106-A5396FE0-7792-46C4-A323-1639AF340A0A Q37868637-6F6FFD26-E3CD-46DA-9DAE-1EC57F3CB4F0 Q37875193-8CB2132A-DFB5-4085-95E1-6F491C646327 Q37903590-89331E86-4019-4647-9213-2AD0EBD3A139 Q37908155-43CE2D07-537C-4A46-8A5E-67A96C4F77F1 Q37937699-1C0929D1-08A5-452A-A0A0-0DB517C1B4C2 Q37978343-34FAF3D1-2027-4476-8E6B-9A7DED93E440 Q37986358-C2F2BD72-1DDE-4E9F-A06F-CDFB95CDC66E Q38109235-31F1856D-4375-43B3-AE06-B39FD5E18A60 Q38122674-312141CB-905D-486A-8CBA-59C650CC3765 Q38182683-2332737D-F771-450A-858B-48E797A046B4

P2860

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

http://www.wikidata.org/entity/Q45250378

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Bortezomib in recurrent and/or ...... s with impared renal function.

@en

Bortezomib in recurrent and/or ...... s with impared renal function.

@nl

type

label

Bortezomib in recurrent and/or ...... s with impared renal function.

@en

Bortezomib in recurrent and/or ...... s with impared renal function.

@nl

prefLabel

Bortezomib in recurrent and/or ...... s with impared renal function.

@en

Bortezomib in recurrent and/or ...... s with impared renal function.

@nl

P1433

Q45250378-AB1E3FB6-06D9-4AA2-B24F-95226314AF5D

P1476

Q45250378-2118E04A-940A-408F-BBEF-371EF0E074B1

P2093

Q45250378-0DAE199D-B74D-4470-BA98-2C178E902F92

Q45250378-3003C47A-FDBF-493D-8078-38D0DAAD9FD3

Q45250378-304C90E1-EC67-49C7-A339-5981EFB6A1C2

Q45250378-4DFE3B52-9533-4332-B8A8-2DCC2AC0F961

Q45250378-5F7268AD-925F-4D7C-9BE1-29120AB1C4B3

Q45250378-7B621D78-60DF-4B6F-B151-96591CB408CC

Q45250378-A19A284F-6028-4DF3-863F-344E30250B83

Q45250378-AAE8C585-CD93-4810-B8DD-F860B3720A5E

Q45250378-F8E4FC63-5F6B-4885-BAD9-C53D6901F047

P304

Q45250378-023A892C-AB18-4E0C-9CF2-BAB29CDB16C5

P31

Q45250378-508A3C56-2841-430F-AA9A-4ADE84BA49C3

P356

Q45250378-D828A4BC-EC62-4D4A-A414-F3541F75FFD3

P407

Q45250378-0A26BB86-BB24-46C0-8186-E934D771D634

P433

Q45250378-5331FFA1-6382-4FEB-B8D9-00BE85C5A4F6

P478

Q45250378-156BCB01-D868-4623-9809-BDD4E467C7FB

P50

Q45250378-133EAB16-F7C4-4EFE-A160-2D501D276129

Q45250378-1D7F74E6-5588-4567-89F3-4E47D0743085

Q45250378-EE1C69DC-3B5E-4C38-AB64-DDB824FE9A34

Q45250378-FAF0CBFB-97BC-43AF-B83B-0E04EA461D22

P577

Q45250378-F7D382EA-FE77-45A8-87D7-3FA562EBD01A

P5875

Q45250378-88E6036D-D936-46DA-84E7-B03E14D009AD

P698

Q45250378-BAC7AED3-274D-4359-BD5C-5DC602861155

P921

Q45250378-3E05F7B2-53D9-4276-8433-ACCB25656E52

P356

P1433

P1476

Bortezomib in recurrent and/or ...... s with impared renal function.

@en

P2093

Darrell Nix

http://www.w3.org/2001/XMLSchema#string

Dixie L Esseltine

http://www.w3.org/2001/XMLSchema#string

Gordan Srkalovic

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Jessica Anderson

http://www.w3.org/2001/XMLSchema#string

Raymond Alexanian

http://www.w3.org/2001/XMLSchema#string

SUMMIT/CREST Investigators

http://www.w3.org/2001/XMLSchema#string

Seema Singhal

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P304

1195-1200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.20888

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

Robert Z Orlowski

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8042870

http://www.w3.org/2001/XMLSchema#string

P698

15690325

http://www.w3.org/2001/XMLSchema#string

P921